France’s medicine regulator has banned the production, sale, and use of two new families of cannabinoid derivatives due to serious side effects and potential addiction. The ban, effective June 3, applies to semi-synthetic and synthetic substances sold online and in shops. Semi-synthetic molecules like H4-CBD and H2-CBD, as well as certain derivatives with a chemical core called benzo[c]chromene, are included in the ban. However, pure CBD, CBN, and four benzo[c]chromene based products remain authorized. The decision to ban these substances was made in response to reported adverse effects and concerns surrounding their addictive properties.
Source link
French medicine regulator bans two cannabinoid derivatives after reported side effects
